These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 7686469)

  • 1. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
    Plosker GL; Faulds D
    Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
    Coukell AJ; Faulds D
    Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Kaklamani VG; Gradishar WJ
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
    Cersosimo RJ; Hong WK
    J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
    Spencer CM; Faulds D
    Drugs; 1994 Nov; 48(5):794-847. PubMed ID: 7530632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
    Findlay BP; Walker-Dilks C
    Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin as adjuvant therapy in breast cancer.
    Earl H; Iddawela M
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
    Conte P; Gennari A; Guarneri V; Landucci E; Donati S; Salvadori B; Bengala C; Orlandini C; Baldini E
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):21-3. PubMed ID: 11396360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin in combination with the taxanes.
    Trudeau M; Pagani O
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracyclines in the treatment of gynecologic malignancies.
    Maluf FC; Spriggs D
    Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
    Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
    Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of epirubicin (Farmorubicin) in the treatment of solid tumours.
    Mouridsen HT; Alfthan C; Bastholt L; Bergh J; Dalmark M; Eksborg S; Hellsten S; Kjaer M; Peterson C; Skovsgård T
    Acta Oncol; 1990; 29(3):257-85. PubMed ID: 2194531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.